Pulmonology · Medical Literature
Qibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.
Abstract
Chronic inflammation in chronic obstructive pulmonary disease (COPD) arises from prolonged interactions among immune cells, functional cells, and inflammatory cytokines. The Qibai Pingfei Capsule (QBPF), a traditional Chinese medicine (TCM), has been utilized clinically for over two decades to treat COPD. However, robust evidence is required to validate its clinical effectiveness. Single-cell RNA sequencing (scRNA-seq) technology offers comprehensive insights into the immune-inflammatory microenvironment of COPD at the single-cell level, providing valuable strategies for integrating TCM into COPD management. To clarify the mechanism of QBPF in treating COPD through scRNA-seq. A randomized, double-blind, placebo-controlled, multicenter study performed to investigate the QBPF efficacy in COPD patients. PBMCs from these patients were subjected to scRNA-seq, and lung tissue scRNA-seq data were obtained from the public database (GEO: GSE162610). The regulatory mechanism of QBPF was confirmed using a COPD rat model. Acute exacerbation frequency was significantly decreased (p = 0.042), and CAT scores improved (p = 0.008) following QBPF treatment. Nevertheless, no significant changes were recorded in lung function, the 6-minute walk test (6MWT), or the mMRC scale. Within the QBPF group, the 6MWT (p < 0.01) and FEV₁/FVC% (p < 0.01) significantly improved from baseline to 3 months. ScRNA-seq confirmed immune dysfunction, especially the depleted NK cells and impaired activation. QBPF altered the expression of functional markers in NK cells of COPD patients, and animal studies confirmed that QBPF enhanced NK cell activity by modulating the expression of hepatitis A virus cellular receptor 2 (HAVCR2) and killer cell lectin-like receptor C2 (KLRC2). Additionally, scRNA-seq analysis revealed impaired immune function in COPD patients, specifically NK cell exhaustion and dysfunction. These findings demonstrated that QBPF can ameliorate and alleviate COPD symptoms, and its therapeutic effects have been linked to its potential to modulate NK cell function. This study provides some evidence that QBPF can improve NK cell activity in COPD.
Clinical relevance
Does Qibai Pingfei Capsule (QBPF), a traditional Chinese medicine, reduce acute exacerbation frequency and improve health-related quality of life in patients with COPD, and what is its mechanistic effect on the peripheral and pulmonary immune-inflammatory microenvironment—specifically NK-cell biology—as characterized by single-cell RNA sequencing? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, placebo-controlled, multicenter clinical trial with embedded single-cell RNA sequencing (scRNA-seq) translational substudy and confirmatory COPD rat-model mechanistic arm","setting":"Multicenter; specific countries and institution types not reported in the abstract. Lung tissue scRNA-seq data derived from public GEO database (GSE162610).","sampleSize":"Not reported in the abstract; per-arm allocation and total enrollment figures are not provided","population":"Patients with COPD (specific GOLD staging, severity criteria, and detailed inclusion/exclusion criteria not reported in the abstract); peripheral blood mononuclear cells (PBMCs) were collected for scRNA-seq substudy","intervention":"Qibai Pingfei Capsule (QBPF), a traditional Chinese medicine formula used clinically in China for over two decades; dose and duration not reported in the abstract","comparator":"Placebo (formulation and matching details not reported in the abstract)","primaryOutcome":"Not explicitly designated as a single primary endpoint in the abstract; outcomes assessed include acute exacerbation frequency and COPD Assessment Test (CAT) score; spirometric parameters (e.g., FEV₁) appear to have been measured but results are not fully reported in the provided abstract text","followUp":"Not reported in the abstract","fundingSource":"Not reported in the abstract"}
Key findings
Based exclusively on the partial abstract provided: QBPF treatment was associated with a statistically significant reduction in acute exacerbation frequency (p = 0.042) and a statistically significant improvement in CAT scores (p = 0.008) compared with placebo. Absolute effect sizes, relative risk reductions, confidence intervals, and NNT values are not reported in the abstract and cannot be calculated. The abstract explicitly states that 'no significant changes were observed' for at least one additional outcome (the abstract text is truncated and the specific non-significant outcome—likely spirometric measures such as FEV₁—is not fully disclosed). The scRNA-seq substudy of PBMCs and public lung-tissue data (GEO: GSE162610) identified NK-cell dysfunction as a mechanistic feature of COPD targeted by QBPF, with mechanistic findings confirmed in a rat COPD model. Specific NK-cell subpopulations affected, the directionality and magnitude of gene-expression changes, and the signaling pathways implicated are not detailed in the available abstract text. No adverse event data are reported in the abstract.
Practice implications
This study provides randomized, placebo-controlled evidence that QBPF reduces acute exacerbation frequency and improves patient-reported symptoms (CAT score) in COPD, both outcomes of direct clinical relevance. However, multiple critical limitations prevent confident clinical translation at this stage. First, only a partial abstract is available; complete outcome data, sample size, GOLD severity distribution, concomitant therapy details, adverse events, and follow-up duration are not accessible, representing a major interpretive constraint. Second, the statistically significant findings (p = 0.042 for exacerbations; p = 0.008 for CAT) carry uncertain clinical magnitude without absolute risk differences or confidence intervals. Third, the explicit statement that at least one additional outcome was not significantly changed—likely pulmonary function—suggests QBPF may improve symptomatic burden and exacerbation risk without modifying underlying airflow obstruction, a distinction of clinical importance. Fourth, the scRNA-seq mechanistic findings (NK-cell dysfunction) are hypothesis-generating and mechanistically suggestive, but translational validity from peripheral blood PBMCs and a rat model to human lung pathophysiology requires independent confirmation. Fifth, the GEO public dataset used for lung-tissue scRNA-seq introduces potential confounding from population heterogeneity and differing COPD phenotypes. The population to which findings apply—in terms of COPD severity, ethnicity, background therapy, and TCM syndrome type—is not adequately characterized in the abstract. Patients outside Chinese clinical practice settings may not be represented. Practice should not change on the basis of this single trial alone; independent replication with full outcome reporting, larger sample sizes, and longer follow-up is required. __LIMITATIONS__ Only a partial abstract is available; the full dataset, complete results, sample size, and safety data are not accessible for critical appraisal,Total sample size and per-arm allocation are not reported, precluding assessment of statistical power or risk of type II error,Absolute effect sizes, confidence intervals, and NNT/NNH are not reported, making clinical magnitude of findings uninterpretable,Follow-up duration is not stated; durability of exacerbation reduction and CAT improvement cannot be assessed,At least one outcome (likely spirometric) was not significantly improved, suggesting dissociation between symptom benefit and disease modification,scRNA-seq substudy is observational and embedded within an RCT; mechanistic conclusions about NK-cell pathways cannot be validated for causality from this design alone,Use of publicly available GEO lung-tissue data (GSE162610) introduces heterogeneity, selection bias, and limited comparability with the trial population,Rat model mechanistic arm introduces cross-species translational uncertainty,PBMC scRNA-seq may not accurately reflect the pulmonary immune microenvironment,Funding source and potential conflicts of interest are not reported, limiting assessment of sponsorship bias,COPD phenotype, GOLD stage, concomitant standard-of-care therapies, and TCM syndrome classification are not described, limiting generalizability,Trial likely conducted predominantly or exclusively in China, limiting applicability to non-Chinese populations and non-TCM clinical systems,Statistical significance (p < 0.05) does not establish clinical meaningfulness without effect size data and minimal clinically important difference (MCID) comparisons for CAT score and exacerbation frequency __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In this randomized, double-blind, placebo-controlled multicenter trial, QBPF significantly reduced acute exacerbation frequency (p = 0.042) and improved CAT scores (p = 0.008) in COPD patients, with scRNA-seq suggesting NK-cell dysfunction as a mechanistic target; however, at least one outcome (likely spirometric) was not significantly changed. Critical data including sample size, absolute effect sizes, confidence intervals, follow-up duration, and adverse events are not available from the partial abstract, precluding definitive clinical appraisal. QBPF cannot yet be recommended for routine COPD management outside investigational or TCM-integrated settings; independent replication with complete reporting is required before any practice adoption.